HEPTALAC Drug Patent Profile
✉ Email this page to a colleague
When do Heptalac patents expire, and when can generic versions of Heptalac launch?
Heptalac is a drug marketed by Teva Pharms and is included in one NDA.
The generic ingredient in HEPTALAC is lactulose. There are twenty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the lactulose profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Heptalac
A generic version of HEPTALAC was approved as lactulose by HIKMA on July 3rd, 1995.
Summary for HEPTALAC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 30 |
Patent Applications: | 3,629 |
Formulation / Manufacturing: | see details |
DailyMed Link: | HEPTALAC at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for HEPTALAC
US Patents and Regulatory Information for HEPTALAC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Pharms | HEPTALAC | lactulose | SOLUTION;ORAL, RECTAL | 073504-001 | May 28, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |